계명대학교 의학도서관 Repository

Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction - Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health.

Metadata Downloads
Author(s)
Min Chul KimMyung Ho JeongDoo Sun SimYoung Joon HongJu Han KimYoungkeun AhnTae Hoon AhnKi Bae SeungDong-Ju ChoiHyo-Soo KimHyeon Cheol GwonIn Whan SeongKyoung-Kook HwangShung Chull ChaeSeung Ho HurKwang Soo ChaJei Keon ChaeSeok Kyu Oh
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
Circulation Journal
Issued Date
2018
Volume
82
Issue
7
Keyword
Percutaneous coronary interventionPrasugrelST elevation myocardial infarctionTicagrelor
Abstract
BACKGROUND:

There is little information regarding comparison of ticagrelor and prasugrel in patients with ST-segment elevation myocardial infarction (STEMI). We sought to compare clinical outcomes between ticagrelor and prasugrel in STEMI.Methods and Results:A total of 1,440 patients with STEMI who underwent successful primary percutaneous coronary intervention were analyzed; the data were obtained from the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Of the patients, 963 received ticagrelor, and 477 received prasugrel. The primary study endpoint was 12-month major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR). MACE occurred in 91 patients (6.3%) over the 1-year follow-up, and there were no differences in the incidence of MACE (hazard ratio [HR] 1.20, 95% confidence interval [CI] 0.76-1.91, P=0.438) between the 2 groups. Analysis by propensity score matching (429 pairs) did not significantly affect the results. The incidence of in-hospital major bleeding events was still comparable between the 2 groups (2.4% vs. 2.5%, odds ratio 0.75, 95% CI 0.30-1.86, P=0.532), and there was no significant difference in the incidence of MACE (5.4% vs. 5.8%, HR 0.98, 95% CI 0.56-1.74, P=0.951) after matching.

CONCLUSIONS:

Ticagrelor and prasugrel showed similar efficacy and safety profiles for treating STEMI in this Korean multicenter registry
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine (의과대학)
Citation
Min Chul Kim et al. (2018). Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction - Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Circulation Journal, 82(7), 1866–1873. doi: 10.1253/circj.CJ-18-0112
Type
Article
ISSN
1346-9843
DOI
10.1253/circj.CJ-18-0112
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41144
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.